Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy and safety endpoints.
These landmark findings validate our ability to uncouple pathological thrombus formation from hemostasis—a breakthrough that has the potential to have far more reaching impact in the medical care of patients with cardiovascular disease.
Asundexian now emerges as an established treatment option addressing a major unmet need among the approximately 5 million people worldwide who experience a new non-cardioembolic ischemic stroke each year.
We are profoundly grateful for our partnership with Bayer and for the invaluable contributions of our global network of investigators and study teams whose dedication made OCEANIC-STROKE possible.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Nov 24, 2025, 10:25Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
-
Nov 24, 2025, 10:06Amirpasha Moetazedian Invites a PHD Student to His Lab to Explore Sustainable Artificial Blood Vessels
-
Nov 24, 2025, 09:41Kamran Hajiyev Reflects on A Week of Innovation, Collaboration, and Scientific Exchange at SVIN 2025
-
Nov 24, 2025, 02:55Do You Know Why Clot Contracts? Marin Pavlov Reflects on Expert PE Conference 2025
-
Nov 24, 2025, 01:10Swarsat K Nath on HemeNext 2025: AI is Real, Measurable, and Already Changing Lives
-
Nov 23, 2025, 15:15Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
-
Nov 23, 2025, 14:57Jesse Landry on SeraGene Therapeutics: Rewriting the Rules of Blood and Bleeding Disorders
-
Nov 23, 2025, 14:49Reza Shojaei: What Truly Motivates Donors And What Keeps Them Coming Back?
-
Nov 23, 2025, 14:48Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction